TABLE 1.

Key characteristics of two Geisinger DNA screening programs.

Characteristics	MyCode® community health initiative (research)	Clinical DNA screening pilot
Purpose	Return clinically actionable confirmed findings from research exome sequences to MyCode participants	Return subset of clinically actionable findings from clinically generated exome sequences to unselected patients at participating clinics
Implementation context	Geisinger population and MyCode participants	Patients receiving care at specific ambulatory clinics (primary and specialty care)
Who offers/delivers the program	Precision health associates (consenters), GCs, genetic counseling assistants funded through the GSC program	Clinicians at select sites as part of clinical practice
Screening model	Opportunistic	Proactive
Genes screened	ACMG SF v2.0 + HFE (c.845G > A, p.C282Y homozygotes)	ACMG SF v2.0
Who discloses results	GSC GCs	• GCs modeling the GSC disclosure process (positive results)
		• Ordering clinician via letter (negative results)
Timeline to result return	6 months–2 years based on sample batch size	6–8 weeks

ACMG, American College of Medical Genetics and Genomics; GC, genetic counselor; GSC, genomic screening and counseling.